Payment overview · 2025
General Payments
$1,288.08
41 reported records · 9 companies
Healthcare provider profile · identity verified
Fan Yang, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1629340948
Verified facts
What the public records show
CMS Open Payments records show Fan Yang, M.D. received $1,288.08 in general payments during 2025 across 41 reported records.
Amgen Inc. accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nexletol, Prolia, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $662.78 | 51.5% | 20 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $174.37 | 13.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $147.71 | 11.5% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.70 | 6.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.24 | 5.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.51 | 3.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.65 | 2.8% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $31.37 | 2.4% | 1 | 2025 |
| AGEPHA Pharma FZ LLC | Unresolved — no canonical attribution shown | $28.75 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,288.08 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $434.13 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $431.05 | 14 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $174.37 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $147.71 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.70 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $83.65 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.77 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.77 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $35.65 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $31.37 | 1 | 2025 |
Source payment records
|
|||||
| LODOCO Normalized: lodoco |
Drug | AGEPHA Pharma FZ LLC | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 20 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 16 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1228 | 383 |
| Vascepa | Icosapent Ethyl | 924 | 250 |
| Amlodipine Besylate | Amlodipine Besylate | 726 | 202 |
| Losartan Potassium | Losartan Potassium | 701 | 214 |
| Diclofenac Epolamine | Diclofenac Epolamine | 578 | 131 |
| Omeprazole | Omeprazole | 563 | 190 |
| Alendronate Sodium | Alendronate Sodium | 493 | 137 |
| Diclofenac Sodium | Diclofenac Sodium | 487 | 151 |
| Donepezil Hcl | Donepezil Hcl | 391 | 140 |
| Ammonium Lactate | Ammonium Lactate | 387 | 112 |
| Fluticasone Propionate | Fluticasone Propionate | 351 | 118 |
| Metformin Hcl | Metformin Hcl | 350 | 111 |
| Meclizine Hcl | Meclizine Hcl | 338 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 332 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 88 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 276 | 119 |
| Montelukast Sodium | Montelukast Sodium | 272 | 75 |
| Gabapentin | Gabapentin | 253 | 75 |
| Azithromycin | Azithromycin | 247 | 176 |
| Trazodone Hcl | Trazodone Hcl | 246 | 82 |
| Simvastatin | Simvastatin | 239 | 71 |
| Finasteride | Finasteride | 208 | 65 |
| Clotrimazole | Clotrimazole | 201 | 56 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 198 | 77 |
| Jardiance | Empagliflozin | 195 | 47 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 187 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 50 |
| Farxiga | Dapagliflozin Propanediol | 166 | 57 |
| Halobetasol Propionate | Halobetasol Propionate | 161 | 61 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 160 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 47 |
| Raloxifene Hcl | Raloxifene Hcl | 142 | 55 |
| Bepotastine Besilate | Bepotastine Besilate | 137 | 41 |
| Lisinopril | Lisinopril | 136 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 130 | 41 |
| Hydrocortisone | Hydrocortisone | 129 | 38 |
| Synthroid | Levothyroxine Sodium | 127 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 124 | 30 |
| Ezetimibe | Ezetimibe | 120 | 48 |
| Mupirocin | Mupirocin | 120 | 52 |
| Januvia | Sitagliptin Phosphate | 116 | 40 |
| Azelastine Hcl | Azelastine Hcl | 114 | 37 |
| Famotidine | Famotidine | 114 | 35 |
| Amoxicillin | Amoxicillin | 111 | 87 |
| Celecoxib | Celecoxib | 106 | 64 |
| Cephalexin | Cephalexin | 106 | 78 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 34 |
| Clobetasol Propionate | Clobetasol Propionate | 103 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 31 |
| Cefdinir | Cefdinir | 89 | 76 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 87 | 38 |
| Dexlansoprazole Dr | Dexlansoprazole | 86 | 28 |
| Ketoconazole | Ketoconazole | 86 | 28 |
| Loperamide | Loperamide Hcl | 84 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 26 |
| Eliquis | Apixaban | 79 | 18 |
| Nitroglycerin | Nitroglycerin | 78 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 39 |
| Allopurinol | Allopurinol | 75 | 30 |
| Metformin Hcl Er | Metformin Hcl | 75 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 74 | 37 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 74 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 13 |
| Carvedilol | Carvedilol | 68 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 20 |
| Meloxicam | Meloxicam | 68 | 49 |
| Xarelto | Rivaroxaban | 68 | 18 |
| Atenolol | Atenolol | 67 | 21 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 66 | 14 |
| Glipizide Er | Glipizide | 65 | 26 |
| Mometasone Furoate | Mometasone Furoate | 64 | 22 |
| Procto-Med Hc | Hydrocortisone | 60 | 26 |
| Creon | Lipase/Protease/Amylase | 57 | 20 |
| Nexium | Esomeprazole Magnesium | 51 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 50 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 11 |
| Lidocaine | Lidocaine | 49 | 16 |
| Folic Acid | Folic Acid | 48 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 11 |
| Fluocinonide | Fluocinonide | 46 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 18 |
| Glipizide | Glipizide | 44 | 15 |
| Fenofibrate | Fenofibrate,micronized | 43 | suppressed |
| Ciclopirox | Ciclopirox | 42 | 13 |
| Enalapril Maleate | Enalapril Maleate | 42 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 41 | 15 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 41 | 12 |
| Olanzapine | Olanzapine | 40 | 12 |
| Spironolactone | Spironolactone | 40 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 16 |
| Furosemide | Furosemide | 37 | suppressed |
| Nexletol | Bempedoic Acid | 37 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 37 | 16 |
| Acarbose | Acarbose | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 15 |
| Valsartan | Valsartan | 35 | 13 |
| Vemlidy | Tenofovir Alafenamide | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 13 |
| Ciclopirox | Ciclopirox Olamine | 33 | 11 |
| Promethazine Hcl | Promethazine Hcl | 32 | 13 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 20 |
| Sucralfate | Sucralfate | 31 | suppressed |
| Erythromycin | Erythromycin Base | 30 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | 19 |
| Nystatin | Nystatin | 28 | 16 |
| Sertraline Hcl | Sertraline Hcl | 28 | 16 |
| Tradjenta | Linagliptin | 28 | suppressed |
| Alogliptin | Alogliptin Benzoate | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | 11 |
| Lactulose | Lactulose | 25 | 12 |
| Tacrolimus | Tacrolimus | 25 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 24 | 11 |
| Colchicine | Colchicine | 24 | 15 |
| Entecavir | Entecavir | 24 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 24 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin Calcium | 21 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Silodosin | Silodosin | 17 | suppressed |
| Prednisone | Prednisone | 16 | 11 |
| Terconazole | Terconazole | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Benzonatate | Benzonatate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Permethrin | Permethrin | 13 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,288.08 · 41 records | Amgen Inc. | ABRYSVO, Arikayce, COMIRNATY, Cologuard Collection Kit, EVENITY, LODOCO, NEXLETOL, OTEZLA, PREVNAR 20, PROLIA, REPATHA, REXULTI, TRELEGY ELLIPTA, VOQUEZNA, VYNDAMAX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nexletol play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error